Xadago is owned by Mdd Us.
Xadago contains Safinamide Mesylate.
Xadago has a total of 3 drug patents out of which 0 drug patents have expired.
Xadago was authorised for market use on 21 March, 2017.
Xadago is available in tablet;oral dosage forms.
Xadago can be used as adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.
Drug patent challenges can be filed against Xadago from March, 2021.
The generics of Xadago are possible to be released after 21 March, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|US8278485||MDD US||Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides|| |
(4 years from now)
|US8076515||MDD US||Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides|| |
(5 years from now)
|US8283380||MDD US||Methods for treatment of parkinson's disease|| |
(8 years from now)
|New Chemical Entity Exclusivity (NCE)||Mar 21, 2022|
NCE-1 date: March, 2021
Market Authorisation Date: 21 March, 2017
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic